Výsledky vyhledávání - Werner Engl

  • Zobrazuji výsledky 1 - 8 z 8
Upřesnit hledání
  1. 1
    Rapid subcutaneous immunoglobulin administration every second week results in high and stable serum immunoglobulin G levels in patients with primary antibody deficiencies

    Rapid subcutaneous immunoglobulin administration every second week results in high and stable serum immunoglobulin G levels in patients with primary antibody deficiencies Autor Rolf Gustafson, Ann Gardulf, Susanne V. Hansen, Heinz Leibl, Werner Engl, Magdalena Lindén, Anne Müller, Lennart Hammarström

    Vydáno 2008
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  2. 2
    Extended half‐life pegylated, full‐length recombinant factor <scp>VIII</scp> for prophylaxis in children with severe haemophilia A

    Extended half‐life pegylated, full‐length recombinant factor <scp>VIII</scp> for prophylaxis in children with severe haemophilia A Autor Eric S. Mullins, Oleksandra Stasyshyn, María Román, David Osman, Ri Liesner, Werner Engl, Marlies Sharkhawy, Brigitt E. Abbuehl

    Vydáno 2016
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  3. 3
    Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study

    Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study Autor Robert Klamroth, Jerzy Windyga, Vlad C. Radulescu, Peter W. Collins, Oleksandra Stasyshyn, Hishamshah Mohd Ibrahim, Werner Engl, Srilatha Tangada, William Savage, Bruce M. Ewenstein

    Vydáno 2020
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  4. 4
    Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficiencies

    Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficiencies Autor Michael Borte, G. Kriván, Beáta Dérfalvi, László Maródi, Thomas Harrer, Stephen Jolles, Christelle Bourgeois, Werner Engl, Heinz Leibl, Barbara McCoy, David Gelmont, Leman Yel

    Vydáno 2016
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  5. 5
    Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency

    Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency Autor Richard L. Wasserman, Isaac Melamed, Mark R. Stein, Sudhir Gupta, Jennifer M. Puck, Werner Engl, Heinz Leibl, Barbara McCoy, Victoria Empson, David Gelmont, Richard I. Schiff

    Vydáno 2012
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  6. 6
    Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A

    Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A Autor Barbara A. Konkle, Oleksandra Stasyshyn, Pratima Chowdary, David Bevan, Tim Mant, Midori Shima, Werner Engl, Jacqueline Dyck-Jones, Monika Fuerlinger, Lisa Patrone, Bruce M. Ewenstein, Brigitt E. Abbuehl

    Vydáno 2015
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  7. 7
    Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency

    Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency Autor Richard L. Wasserman, Isaac Melamed, Mark R. Stein, Werner Engl, Marlies Sharkhawy, Heinz Leibl, Jennifer M. Puck, Arye Rubinstein, Lisa Kobrynski, Sudhir Gupta, Andrew J. Grant, Anoshie Ratnayake, Wendell Richmond, Joseph A. Church, Leman Yel, David Gelmont

    Vydáno 2016
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  8. 8
    Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial

    Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial Autor Pier Mannuccio Mannucci, Christine L. Kempton, Carolyn M. Millar, Edward H. Romond, Amy D. Shapiro, Ingvild Birschmann, Margaret V. Ragni, Joan Cox Gill, T. T. Yee, Robert Klamroth, Wing-Yen Wong, Miranda Chapman, Werner Engl, Peter L. Turecek, Tobias M. Suiter, Bruce M. Ewenstein

    Vydáno 2013
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:

Vyhledávací nástroje: